BeiGene Ends Development of Ociperlimab Following Phase 3 Lung Cancer Trial Setback ###

Ociperlimab Program Suspension:
BeiGene has terminated the development of ociperlimab (BGB-A1217) after a Phase 3 trial (AdvanTIG-302) showed futility in improving overall survival in patients with untreated non-small cell lung cancer (NSCLC)1 2.

Phase 3 Results:
The decision was guided by an independent data monitoring committee that found the trial unlikely to meet its primary endpoint of overall survival, although no new safety concerns were identified1 2.

TIGIT Class Struggles:
Ociperlimab, a monoclonal antibody targeting the TIGIT pathway, joins a growing list of failed anti-TIGIT drugs, including similar setbacks from Roche, Merck, and others in NSCLC clinical trials1 3 5.

Previous Challenges:
BeiGene's ociperlimab program faced earlier struggles, such as the departure of Novartis as a partner in 2023 and the discontinuation of related trials, including AdvanTIG-301 and AdvanTIG-306, due to lackluster data and strategic re-evaluation1 3.

Industry Impacts:
BeiGene’s decision highlights an overall decline in enthusiasm for anti-TIGIT therapies, leaving AstraZeneca and GSK/iTeos as key players still pursuing this pathway in clinical settings3 4.

Future Insights Promised:
BeiGene intends to share detailed results from the AdvanTIG-302 study to advance scientific understanding of anti-TIGIT mechanisms2 5.